NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

This study is to assess for Measurable Residual Disease (MRD) in multiple myeloma at a deeper level than what is currently available by combining novel imaging and laboratory techniques, determine if patients who are MRD-negative by these multiple modalities can safely and effectively discontinue post-transplant maintenance therapy, and determine if liquid biopsies is a more accurate and/or less invasive sampling technique for multiple myeloma.

The purpose of this research is to determine if patients who are MRD-negative by multiple modalities ("multimodality MRD-negative") can safely and effectively discontinue post-transplant maintenance therapy (single agent lenalidomide, pomalidomide, bortezomib, or ixazomib) after receiving at least one year of maintenance therapy.

Sponsor:

University of Chicago

Location

United States, Illinois

---

ClinicalTrials.gov Identifier: NCT04108624

Official Title: A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple Myeloma (MRD2STOP)

First Posted: September 30, 2019

Click here for details on ClinicalTrials.gov

---

MRD Testing

Adaptive Biotechnologies

---

Location

United States, Illinois